Christine obtained her PhD in Molecular Biology and Biochemistry at the University Massachusetts Medical School. She then went on to do a postdoctoral fellowship at the Center for Neurodegeneration at BWH/Harvard Medical School. Following her postdoc she joined Archemix, a biotechnology company in Cambridge MA specializing in the discovery and development of therapeutic aptamers. She joined GSK in 2011 to lead and develop an aptamer discovery platform at the GSK site in Waltham MA which was home to GSK’s Encoded Library Technology. In 2013, she took over as lead of the Encoded Library Technology platform. This platform develops DNA encoded libraries which contain billions of small molecule compounds which are screened using an affinity-based selection methodology in a single binding reaction. This small molecule discovery platform complements the other internal screening methodologies including high throughput screening and fragment-based drug discovery. In 2016, Christine was appointed VP of NCE Molecular Discovery. This organization is home to GSK’s small molecule discovery technology platforms including the ELT platform, high throughput screening and compound profiling, small molecule compound handling, chemical biology, the PROTACs technology and analytical chemistry support for the medicinal chemistry team. She is also Site Head for the GSK Discovery site in Cambridge Massachusetts.